Updated 8/10/2026
Bright red with white spots, Amanita muscaria, often called the “fly agaric” mushroom, is one of the most recognizable mushrooms in the world. But beyond its storybook appearance, this mushroom is increasingly being marketed and sold across the United States in gummies, chocolates, tinctures, capsules, and dried caps.
In recent years, Amanita muscaria products have appeared in gas stations, smoke shops, and online retailers. Some individuals are using these products as alternatives to psilocybin, alcohol, or prescription medications. However, growing public health concerns center around unpredictable effects, inconsistent potency, mislabeling, and a lack of regulation. At Hanley Center, we believe education is essential. Here’s what you need to know.
What Is Amanita Muscaria?
Amanita muscaria is a psychoactive mushroom that contains two primary active compounds:
- Muscimol
- Ibotenic acid
Unlike “magic mushrooms,” which contain psilocybin, Amanita muscaria works differently in the brain.
- Psilocybin primarily affects serotonin receptors.
- Muscimol primarily acts on the GABA system, which influences sedation, relaxation, and inhibition.
- Ibotenic acid acts on glutamate receptors and can have excitatory, potentially toxic effects.
Because it acts on different brain systems, the experience of Amanita muscaria is often described as more sedative, dissociative, or delirium-like rather than psychedelic in the traditional sense.
How Is Amanita Muscaria Being Sold?
Amanita muscaria is increasingly marketed in commercial forms, including:
- Gummies
- Chocolates
- Capsules or tablets
- Drink mixes and shots
- Tinctures
- Dried mushroom caps
- Extract powders
Many of these products are available:
- At gas stations
- In smoke shops
- Through online retailers
- Via social media advertising
Because Amanita muscaria is not regulated like prescription medications, product potency, preparation, and ingredient transparency can vary widely. Some online discussions suggest that certain products may be mislabeled, inconsistently dosed, or potentially adulterated. This lack of regulatory oversight increases risk.
What Are the Short-Term Effects of Amanita Muscaria?
Reported short-term effects may include:
- Sedation or extreme drowsiness
- Confusion
- Disorientation
- Nausea and vomiting
- Muscle twitching
- Agitation
- “Dream-like” or delirious states
- Loss of coordination
- Difficulty distinguishing reality from imagination
Some individuals describe a state where they feel trapped between wakefulness and sleep, with vivid hallucinations or dream sequences blending into reality. There have also been reports of dangerous behaviors during intoxication, including accidental injury due to impaired judgment and confusion.
What Are the Potential Adverse Effects?
Research on the long-term effects of Amanita muscaria is limited. However, poisoning and intoxication have been associated with symptoms such as:
- Visual and sensory disturbances
- Confusion and disorientation
- Agitation or unusual behavior
- Hallucinations
- Drowsiness or changes in consciousness
- Nausea and vomiting
- Seizures in severe cases
Symptoms can vary considerably depending on the amount consumed, the concentration of active compounds, and whether a commercial product contains additional or undisclosed ingredients.
Why Are People Using It?
People are using it as:
- As a substitute for alcohol
- As an alternative to psilocybin
- For self-medication and “microdosing” to manage anxiety or depression
- As self-medication to reduce withdrawal symptoms from benzodiazepines or gabapentinoids
- As part of “stacking” protocols (combining with LSD, psilocybin, or cannabis)
However, self-medicating with unregulated psychoactive substances can increase the risk of:
- Worsening mental health symptoms
- Substance dependence
- Accidental overdose
- Drug interactions
- Complicated withdrawal
Is Amanita Muscaria Addictive?
There is limited research on addiction potential. However, any substance that alters mood, sedation, or perception can become psychologically reinforcing.
People who use Amanita muscaria to cope with anxiety, depression, trauma, sleep problems, or withdrawal symptoms may be at greater risk of developing patterns of psychological dependence. In some cases, repeated use can worsen underlying mental health conditions or contribute to polysubstance use. Individuals experiencing both substance use and mental health concerns may benefit from treatment that addresses co-occurring mental health disorders together rather than separately.
There is a risk of developing a pattern of reliance. At Hanley Center, we often see individuals who began using alternative or “legal” psychoactive products believing they were safer, only to find themselves struggling with dependency, worsening mental health symptoms, or polysubstance use.
Is Amanita Muscaria Legal In the United States?
One reason Amanita muscaria has grown in popularity is confusion around its legal status. Unlike psilocybin (“magic”) mushrooms, Amanita muscaria is not listed as a Schedule I substance under the federal Controlled Substances Act. That means it is technically legal to possess and cultivate at the federal level. However, legal does not mean approved or safe.
As of December 2024, the U.S. Food and Drug Administration (FDA) moved to restrict the use of Amanita muscaria in food products, including edibles. The FDA has stated that Amanita muscaria is considered a poisonous substance and is not approved for use in foods, beverages, or dietary supplements.
Key distinctions include:
- Not scheduled federally under the Controlled Substances Act
- Not FDA-approved for human consumption
- Classified as poisonous by federal authorities
- Restricted from use in food products as of December 2024
- State laws may vary; Louisiana currently has specific prohibitions on the sale for human consumption
Despite these restrictions, Amanita muscaria products are still widely available online and may be found in smoke shops, gas stations, and specialty retailers. This regulatory gray area has created significant confusion for consumers.
Why Has the FDA Restricted Amanita Muscaria Edibles?
The FDA’s 2024 action followed reports of:
- Poisonings
- Severe sedation
- Neurological complications
- Emergency room visits
- Deaths linked to mushroom-containing edible products
Unlike psilocybin, Amanita muscaria contains muscimol and ibotenic acid, compounds that act on GABA and glutamate receptors rather than serotonin receptors.
Improper preparation, particularly failure to adequately convert ibotenic acid into muscimol through decarboxylation, has been associated with:
- Severe nausea
- Agitation
- Delirium
- Confusion
- Loss of motor control
Even when prepared intentionally for muscimol conversion, high doses can cause:
- Extreme sedation
- Amnesia
- Disorientation
- Risk of accidental injury
The variability in preparation significantly increases unpredictability. Because these products are sometimes marketed as “legal mushroom gummies” or positioned as alternatives to alcohol or psilocybin, consumers may underestimate the risks.
Amanita Muscaria vs. Psilocybin: What’s the Difference?
Amanita muscaria is often confused with “magic mushrooms,” but they are chemically and legally distinct.
| Active compounds: muscimol & ibotenic acid | Active compound: psilocybin |
| Acts on GABA/glutamate systems | Acts on serotonin receptors |
| Not federally scheduled | Schedule I federally |
| Not FDA-approved | Also not FDA-approved |
| Often sold in retail edible products | Rarely sold legally outside research settings |
Both substances can alter perception, but their mechanisms, effects, and risks differ significantly.
Getting Help For Substance Use Concerns
If you or a loved one has used Amanita muscaria and is experiencing:
- Persistent confusion
- Severe anxiety
- Visual disturbances
- Blackouts or amnesia
- Ongoing sedation
- Difficulty distinguishing reality from dream-like states
- Continued use despite negative consequences
It may be time to seek a professional evaluation.
Emerging psychoactive substances like Amanita muscaria can affect both mental and physical health. Some individuals experience lingering symptoms that interfere with daily life, while others begin using these products more frequently to manage stress, sleep problems, anxiety, or emotional distress.
At Hanley Center, we provide integrated care for:
- Substance use disorders
- Substance-induced mental health conditions
- Co-occurring anxiety, mood, and trauma disorders
- Emerging drug trends and novel psychoactive substances
Our team offers comprehensive co-occurring disorders treatment and evidence-based addiction treatment programs to address both the physical and psychological effects of substance use.
Emerging psychoactive products are often marketed as natural or safer alternatives. However, natural doesn’t always mean safe, especially when products are unregulated, inconsistently dosed, or used to self-medicate mental health symptoms.
If you’re concerned about your use or worried about someone you love, compassionate and confidential help is available. Contact our admissions team or call Hanley Center at (561) 841-1033 to learn more about your treatment options.
Frequently Asked Questions
Is Amanita Muscaria Legal In the United States?
Amanita muscaria is not currently listed as a Schedule I controlled substance under federal law, so possession and cultivation are generally legal at the federal level. However, the FDA does not approve Amanita muscaria for use in foods, beverages, or dietary supplements, and some states have additional restrictions on its sale.
How Is Amanita Muscaria Different From Psilocybin Mushrooms?
Amanita muscaria contains muscimol and ibotenic acid, which affect GABA and glutamate receptors in the brain. Psilocybin mushrooms affect serotonin receptors. As a result, Amanita muscaria is more commonly associated with sedation, confusion, and delirium-like experiences rather than traditional psychedelic effects.
What Are The Symptoms of Amanita Muscaria Poisoning?
Symptoms may include nausea, vomiting, confusion, agitation, extreme drowsiness, loss of coordination, hallucinations, and difficulty distinguishing reality from dream-like states. Severe cases may require emergency medical attention.
Are Amanita Muscaria Gummies Safe?
No Amanita muscaria products have been approved by the FDA for human consumption. Because these products are largely unregulated, potency, ingredients, and preparation methods can vary significantly. Some products may be mislabeled or contain inconsistent amounts of psychoactive compounds, increasing the risk of adverse effects and poisoning.
Can Amanita Muscaria Cause Long-Term Mental Health Effects?
Research is still emerging, but some individuals report lingering symptoms such as disturbing dreams, visual disturbances, depersonalization, and increased anxiety. People with underlying mental health conditions or substance use disorders may be particularly vulnerable to adverse effects.
Where Can Someone Get Help for Mushroom or Psychedelic Use Concerns?
Professional help is available for individuals experiencing adverse effects, problematic use, or co-occurring mental health concerns related to Amanita muscaria or other psychoactive substances.
Hanley Center provides integrated treatment for substance use disorders, mental health conditions, and emerging drug trends in a compassionate, confidential setting. Call Hanley Center at (561) 841-1033 to learn more.
References
U.S. Food and Drug Administration (FDA). (2024). FDA Alerts Industry and Consumers about the Use of Amanita Muscaria or its Constituents in Food.
FDA: Amanita muscaria safety alert
U.S. Food and Drug Administration (FDA). (2024). Scientific Memorandum: Amanita Muscaria.
FDA Scientific Memorandum: Amanita Muscaria
Michienzi, A., Hamlin, J., Farah, R., & colleagues. (2024). Notes from the Field: Schedule I Substances Identified in Nootropic Gummies Containing Amanita muscaria or Other Mushrooms — Charlottesville, Virginia, 2023–2024. Morbidity and Mortality Weekly Report, 73, 628–630.
CDC study on Amanita and mushroom gummies
Moss, M. J., & Hendrickson, R. G. (2019). Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002–2016. Clinical Toxicology, 57(2), 99–103.
PubMed: Moss & Hendrickson study
Taylor, J., Holzbauer, S., Wanduragala, D., et al. (2019). Notes from the Field: Acute Intoxications from Consumption of Amanita muscaria Mushrooms — Minnesota, 2018. Morbidity and Mortality Weekly Report, 68, 483–484.
CDC: Acute Amanita muscaria intoxication
Michelot, D., & Melendez-Howell, L. M. (2003). Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycological Research, 107(2), 131–146.
PubMed: Amanita muscaria review
Johnston, G. A. R. (2014). Muscimol as an ionotropic GABA receptor agonist. Neurochemical Research, 39(10), 1942–1947.
PubMed: Muscimol and GABA receptors
U.S. Food and Drug Administration (FDA). (2024). Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies.
FDA Diamond Shruumz investigation
Rumph, J. T., Winquist, A., Troeschel, A. N., et al. (2026). Severe Illness Associated with Eating Mushroom-Containing Chocolate Products — United States, January–October 2024. Morbidity and Mortality Weekly Report, 75, 179–184.
CDC 2026 mushroom-containing chocolate report